Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.

Abstract: A process for creating an executable configuration that can be run on a target system by selecting from a library a number of abstracted software components that are independent of the target system that implement individual functions of the target system and that are provided with a specified command interface and a specified interface to data channels, the selected software components that are independent of the target system are interconnected via their data channels for the realization of the automatization task to a model which is automatically transformed by a model transformation into a net list of nodes, attributes and edges, whereby the software components form the nodes, the initial parameters, the attributes and the data channels the edges of the net list, the software components that are independent of the target system are transformed into software components dependent on the target system, the software components that are dependent on the target system are instantiated at the target system and p

Abstract: The automatization unit used in current test stands is a central system in which various interfaces are connected with the individual test stand components. As a result, an inflexible system is created with limited scalability, as numerous changes are required in the automatization unit, for example, a new interface, processing of data from/to the component, integration into the existing system, etc. in order to integrate new components (SW and HW). This makes a change or an enhancement of the automatization unit, the implementation of specific customer requests or the integration of an external functionality very expensive.

Abstract: Ready-to-use, aqueous injection solutions containing carvedilol (1-(9H-carbazolyl-4-yloxy)-3-[[(2-(2-methoxyphenoxy)ethyl]-amino]-2-propanol) or its pharmacologically harmless salts which are stable in storage and are well tolerated by veins are disclosed.

Abstract: The object of the invention are ready-to-inject, aqueous injection solutions containing carvedilol (1-(9H-carbazolyl)-3-[[2-(2-methoxyphenoxy)ethyl]-amino]-2-propanol) or its pharmacologically harmless salts as well as a process for their production. The injection solutions are stable on storage and are well tolerated by veins.

Abstract: A process for the production of a rubber-to-metal bond on steel, galvanized steel, aluminum and/or magnesium is provided The process comprises at least the following steps: a) chemical pretreatment of the metal parts, b) intermediate rinsing, and c) vulcanizing-on of natural or synthetic rubber using primers and/or binders. The chemical pretreatment in step a) is carried out with an aqueous solution with a pH value of 3.5 to 5.5 which contains: 4 to 20 g/l of phosphate ions, 0.1 to 1 g/l of free or complexed fluoride, and 0.04 to 1 g/l of nitrate ions.

Abstract: The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.

Abstract: Cyanoacrylate adhesives which have increased heat resistance, yet also exhibit good storage stability and acceptable cure times, are obtained by using 2-cyanopentadienoic acid esters in combination with alkylene bis-(2-cyanopentadienoates).

Abstract: Biscyanoacrylates in solution are prepared by reacting 2-cyanoacrylic acids or their alkyl esters with diols in the presence of sulfonic acids as catalysts. The reaction mixture is processed by substituting an aliphatic solvent for the aromatic solvent and is then subjected twice to fractional crystallization. The thus obtained biscyanoacrylates are very pure. They are therefore useful for producing storage stable cyanoacrylate adhesives. Their admixture increases the thermal resistance of the adhesives, which is particularly important in the case of electric and electronic components.

Abstract: Compositions containing p-dinitrosobenzene deposited onto a support of a chemically inert material which is solid at room temperature are provided. The composition is preferably formed by depositing p-dinitrosobenzene from a solution or by sublimation or in the course of its synthesis in the presence of one or more supports. Hydrophilic or hydrophobic silica, hydrophobicized zeolites, carbon blacks and layer silicates are examples of supports. The composition is useful in the production of adhesives, more particularly for bonding elastomers, e.g. in the polymerization or crosslinking of elastomers, and even more particularly in the bonding of rubber to metal.